Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...
Advertisement Specific types of immune cells unleashed by cancer immunotherapy appear to cause myocarditis, an ...
Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of heart inflammation called myocarditis. Researchers have now uncovered the ...
TIL-Tregs specifically increase GLUT3 expression for glucose uptake in tumors. - GLUT3 fuels protein O-GlcNAcylation, ...
Nomic Bio Inc. (Nomic), a proteomics company with the highest-throughput platform for multiplexed protein quantification, and ...
News Medical on MSN7d
Virtual screening yields small molecules to enhance cancer immunotherapyThe process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine ...
The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can ...
The heart tissue showed upregulation of molecular pathways that help recruit and retain immune cells involved in inflammation ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Dr. Watanabe and his team from Niigata University have revealed that PET/CT image analysis using artificial intelligence (AI) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback